At Under $1, SPRC May Be the Biggest Growing Story Hiding on the NASDAQ!
Greetings All,
The legal MJ industry is expected to expand exponentially in the coming years and savvy investors are seeking to profit. It was just last October that President Biden announced MJ reforms which could be the stepping stone for the U.S. to decriminalize the plant on a federal level.
In the meantime, as more states in the U.S. and countries decriminalize or legalize the plant and/or its components, there is a growing opportunity on Wall Street to enter the space.
With that said, put your attention to SciSparc (SPRC) a small-cap NASDAQ biotech company trading under $1 a share and has an incredibly small trading float!
SPRC has been climbing the ranks of the pharma industry and is revolutionizing the way the world approaches modern medicine through cannabinoids and psychedelics!
This specialty clinical-stage pharmaceutical company is focusing on the development of therapies to treat disorders of the central nervous system. Led by an experienced team of senior executives and scientists, the company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.
The stock has been climbing higher since the year started and there could be more upside ahead given the tiny supply of shares available and because the company had several big announcements this month.
Shares have been on the rise since SPRC announced last week an update on its joint venture with MitoCareX Bio. The latter has reached its very first milestone of setting up a "cloud-based computing infrastructure" and now SPRC is further investing in the joint venture and increasing its stake in the company.
MitoCareX Bio (which focuses on the discovery and development of potential drugs for cancer, rare diseases and other life-threatening conditions) is currently performing virtual screening activities as well as further developing its computationally based drug discovery platform to enable its planned machine learning capabilities.
As a result of MitoCareX Bio meeting this milestone, SPRC will invest an additional $400,000 in MitoCareX Bio and increase its share ownership in MitoCareX Bio from 31.48% to 41.92%.
Earlier this month SPRC also announced that as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, three provisional patent applications were filed by Clearmind with the United States Patent and Trademark Office ("USPTO").
"These new patent applications continue to support our findings of the major role CannAmideTM, our proprietary PEA formulation, plays in SciSparc's various proprietary combination treatments," said Oz Adler, Chief Executive Officer of SciSparc.
"All our clinical and pre-clinical studies performed to date, in numerous diseases and conditions, indicated CannAmide™ ability to reduce doses while maintaining therapeutic efficacy and while increasing safety. We have great confidence in our collaboration with Clearmind and believe that together we can maximize the therapeutic effect of our products, potentially offering additional solutions for mental health problems with unmet needs that have limited effective solutions, if at all," continued Mr. Adler.
With so many people around the world suffering from conditions that have no known cure, it's become vital that research and more is done to help these people and the symptoms they endure as a result of these conditions.
With strong leadership, exciting joint ventures, as well as a growing $6M+ market cap and a small trading float, SciSparc Ltd. (NASDAQ: SPRC) is an emerging NASDAQ company that looks positioned to shine bright in the market!
https://scisparc.com/
SciSparc Ltd.
NASDAQ: SPRC
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules.
Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy.
The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form.
It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation.
SPRC is well aware of the cannabinoid opportunity in the world of pharmaceuticals and the company is dedicated to developing unique cannabinoid technologies for the treatment of central nervous system disorders.
The global cannabis pharmaceutical market size is expected to reach $127.1 billion by 2028!
Robust IP Portfolio:
Repurposing previously approved compounds qualifies SPRC to take advantage of the FDA's 505 (b)(2) application protocol. This potentially means lower risk, and an expedited development timeline. The result is a robust pipeline of product candidates well positioned to create significant shareholder value into the future.
SciSparc has built an intellectual property portfolio which currently comprises three granted U.S. patents and pending patent applications in six families, all focused on disorders of the central nervous system.
Currently, the company's drug candidates are designed to treat Tourette Syndrome, Autism Spectrum Disorder, Epilepsy, Obstructive Sleep Apnea, Alzheimer's Disease and Agitation, and Pain.
The company's research and development efforts are focused on creating a proprietary and unique combination of products, some available already in the market (CannAmide™), products in the accelerated regulatory path of 505 (b)(2) application (SCI-110, SCI-210) and
products that constitute a new chemical entity (SCI-160) in order to bring different products to market at different timelines and potentially enable them to generate immediate revenues for the company.
Drug Candidates:
SCI-110—proprietary drug candidate containing Dronabinol (FDA approved synthetic form of THC), with PEA.
- Designed to stimulate cannabinoid receptors across the Central Nervous System and inhibit the metabolic degradation of endocannabinoids and improve the uptake of THC.
- Expected benefits are an increase in efficiency of oral administration, and in turn a decrease in dosage requirements, side effects and adverse events.
- Being tested for treatment of Tourette Syndrome ("TS")- phase IIb, and Alzheimer's Disease and Agitation- phase IIa.
- Results from Phase IIa clinical trial in TS, conducted at Yale University, showed average tic reduction of 21% across the entire sample with almost 40% experiencing a greater than 25% reduction in tics.
SCI-210—proprietary drug candidate containing CBD and PEA.
- Initially being developed under the regulation of the Israeli Medical Cannabis Agency and Ministry of Health.
- SciSparc intends to further develop the product for markets outside of Israel.
- Being investigated for Autism Spectrum Disorder (in clinical trials) and Status Epilepticus, which is a form of seizures that are severe and sometimes fatal (preclinical trials).
SCI-160—proprietary synthetic CB2 receptor agonist created for the treatment of pain and currently in pre-clinical studies.
- The CB2 receptor agonist used in this formulation (HU-433) was invented and synthesized by the Chairman of the SciSparc Scientific Advisory Board and is under a patent granted in the U.S. and Europe.
Joint Ventures:
Joint Venture Agreement with MitoCareX Bio Ltd.
Not long ago, SPRC announced completion of its previously announced joint venture agreement to focus on the discovery and development of potential drugs for cancers and other life-threatening conditions, with MitoCareX Bio Ltd., an Israeli corporation.
MitoCareX Bio will focus on investigating mitochondrial carriers, transport proteins crucial for cell viability.
Because of mitochondrial carriers' significant role in transporting necessary metabolites for cell functioning across the inner mitochondrial membranes, the company believes various life-threatening conditions, such as cancers and rare mitochondrial diseases, might be treated by regulating the function of mitochondrial carriers!
In humans, the mitochondrial carrier family (Solute Carrier Family 25, SLC25) consists of 53 members and is the largest solute transporter.
Details of the JV agreement can be found HERE.
Joint Pre-Clinical Trial with Clearmind Medicine Inc.
SPRC has revealed positive safety profile results from its joint pre-clinical trial with Clearmind Medicine Inc., (CSE: CMND), (OTC: CMNDF), (FSE: CWY0), a psychedelic pharmaceutical company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems.
The trial tested the proprietary combination of SPRC's CannAmide™ with Clearmind's psychedelic molecule, MEAI, for alcohol consumption.
The results of this ground-breaking research show potential for the first dedicated cocaine addiction treatment! You can read about the trial HERE.
Market Opportunities:
A CDC study using parent-reported data found that 1 out of every 333 (0.3%) children 3–17 years of age in the United States have received a diagnosis of TS; this is about 174,000 children in 2016–2019. This suggests that about half of children with TS may not be diagnosed.
A market opportunity is not one to dismiss…
The Tourette Syndrome market is expected to gain growth at a potential rate of 5.5% in the forecast period of 2021 to 2028. The rise in research and development activities is the factor responsible for the market growth.
The global Tourette's syndrome drugs market size is poised to reach USD 98.77 million by 2023, according to a new report by Technavio, progressing at a CAGR of 5% during the forecast period.
ASD is a condition related to brain development that impacts how a person perceives and socializes with others, causing problems in social interaction and communication. The term "spectrum" in autism spectrum disorder refers to the wide range of symptoms and severity.
The global autism spectrum disorder treatment market size was valued at USD 1.85 billion in 2021. The market is projected to grow from USD 1.93 billion in 2022 to USD 3.17 billion by 2029, exhibiting a CAGR of 7.4% during the forecast period.
According to the Centers for Disease Control and Prevention (CDC), about 1% of the world's population has autism spectrum disorder – over 75,000,000 people.
Major Developments:
SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center
SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment
SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial
In Summary…
While the usage of cannabis has been popular in recent years, it's only very recently that we are discovering the rare cannabinoid potential. Early studies have shown the exciting efficacy of cannabinoids against a large variety of diseases. For example, preclinical and clinical studies have suggested a potential value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia.
Psychedelics have also become an increasingly popular area for medical research and studies. A report by Market Digits estimates that the sector could be worth more than $10 billion by 2027, up from $4.75 billion in 2020!
SPRC is pioneering the way by developing unique cannabinoid technologies for the treatment of central nervous system (CNS) disorders. The company is also combining cannabinoids with already approved treatments.
Excitingly the company is pursuing a restructuring plan which involves transferring its pharmaceutical activities to a new wholly-owned subsidiary.
There's a lot going on with this company and at under $1, this could be a pivotal time to have SPRC on your radar!
START YOUR RESEARCH!
No comments:
Post a Comment